A double-blind, randomized, placebo-controlled video capsule endoscopy trial on the safety and efficacy of Rifaximin-EIR 800 mg BID to prevent intestinal injury caused by a two-we…
W Dolak, C Scarpignato, A Lanas, P Matzneller, M Fogli, M Grimaldi, M Zeitlinger, I Bjarnason · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: Proton pump inhibitors (PPIs) may worsen non-steroidal anti-inflammatory drug (NSAID) induced enteropathy by impairing the intestinal microbiota. Rifaximin is an antimicrobial drug which covers a broad spectrum of enteric pathogens. The aim of this study was to evaluate the safety and efficacy of Rifaximin-EIR, a delayed-release formulation of coated microgranules of rifaximin, to prevent small bowel lesions in healthy volunteers receiving NSAIDs and PPIs. Methods: In this double-blind, randomized, placebo-controlled, phase-I/II trial (EudraCT 2013 – 000730 – 36) healthy volunteers were randomized to…
